Based on the VanEck Genomics and Healthcare Innovators UCITS ETF EUR stock forecast from 0 analysts, the average analyst target price for VanEck Genomics and Healthcare Innovators UCITS ETF EUR is not available over the next 12 months. VanEck Genomics and Healthcare Innovators UCITS ETF EUR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of VanEck Genomics and Healthcare Innovators UCITS ETF EUR is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, VanEck Genomics and Healthcare Innovators UCITS ETF EUR’s stock price was EUR 17.06. VanEck Genomics and Healthcare Innovators UCITS ETF EUR’s stock price has changed by +1.88% over the past week, -7.55% over the past month and -10.39% over the last year.
No recent analyst target price found for VanEck Genomics and Healthcare Innovators UCITS ETF EUR
No recent average analyst rating found for VanEck Genomics and Healthcare Innovators UCITS ETF EUR
Company Overview VanEck Genomics and Healthcare Innovators UCITS ETF EUR
Frequently Asked Questions About VanEck Genomics and Healthcare Innovators UCITS ETF EUR (CURE:XETRA) Stock
Stock Target Advisor's fundamental analysis for VanEck Genomics and Healthcare Innovators UCITS ETF EUR's stock is Bearish.
CURE:XETRA stock's dividend yield is 0.09%.
Based on this CURE:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on CURE:XETRA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CURE:XETRA's stock to indicate if its overvalued.
The last closing price of CURE:XETRA's stock was EUR 17.06.
The most recent market capitalization for CURE:XETRA is EUR 6.89M.
Unfortunately we do not have enough analyst data on CURE:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains VanEck Genomics and Healthcare Innovators UCITS ETF EUR's stock.
Sorry, we do not have any data on the number of employees for VanEck Genomics and Healthcare Innovators UCITS ETF EUR.
Sorry we do not have any infomation available on VanEck Genomics and Healthcare Innovators UCITS ETF EUR's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CURE:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
